Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2021-03-30 AGM Information
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Proxy Form
AGM Information Classification · 99% confidence The document explicitly mentions the 'Annual General Meeting' (AGM) multiple times, including the date, location, and details about voting procedures via a 'Proxy Form'. It also references an accompanying 'shareholder engagement event' which is related to the AGM. The core content is the mechanism for shareholders to vote on resolutions for the upcoming AGM. This directly aligns with the definition of 'AGM Information' (AGM-R), which covers presentations and materials shared during the AGM, and the proxy form is a key material for the meeting.
2021-03-30 English
Notice of AGM
AGM Information Classification · 100% confidence The document explicitly begins with the title "Notice of AGM" and "Notice of Annual General Meeting 2021 and Shareholders' Circular". It details the arrangements for the upcoming Annual General Meeting (AGM) on Tuesday 11 May 2021, including procedures due to COVID-19 restrictions, and outlines the resolutions to be voted upon (Accounts, Dividend, Auditor reappointment, Director elections/re-elections, Remuneration Report/Policy, Political donations, and Allotment of new shares). This content is characteristic of materials sent to shareholders to inform them about the meeting and solicit their votes, which aligns perfectly with the definition of an AGM-related document, specifically a Notice of Meeting/Shareholders' Circular. While it mentions the Annual Report and Remuneration Report, the document itself is the notice calling the meeting and presenting the business to be conducted there, making 'AGM-R' the most appropriate classification over '10-K' or 'DEF 14A'.
2021-03-30 English
FORM 6-K
AGM Information Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which includes a detailed Notice of Annual General Meeting (AGM) for 2021 and a Shareholders' Circular. It contains information about the AGM arrangements, resolutions to be voted on, including accounts and dividend approvals, reappointment of auditors, election and re-election of directors, remuneration reports, political donations, and allotment of new shares. The content is focused on the AGM event and related shareholder information rather than the full annual report or financial statements themselves. The document is lengthy (15,000 characters) and contains substantive AGM-related materials, not just an announcement or a brief notice. Therefore, the appropriate classification is AGM Information (AGM-R).
2021-03-30 English
Notice of AGM
AGM Information Classification · 98% confidence The document explicitly states it is a 'Notice of Annual General Meeting 2021 and Shareholders' Circular'. It details the date, time, and location of the AGM, encourages proxy voting, and lists the business to be conducted at the AGM (including receiving accounts, confirming dividends, and electing directors). This content directly relates to the preparation and announcement of the Annual General Meeting. Although it mentions the Annual Report was published separately, the primary purpose of this specific document is the AGM notice. Therefore, the most appropriate classification is AGM Information (AGM-R).
2021-03-30 English
DIRECTOR/PDMR SHAREHOLDING
Director's Dealing Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer submitted to the SEC. The content details transactions by Persons Discharging Managerial Responsibilities (PDMRs) involving acquisition of ordinary shares pursuant to vesting under the AstraZeneca Deferred Bonus Plan and Performance Share Plan. It includes specific shareholding changes by directors and executives, with dates and transaction details. This type of filing corresponds to insider transactions or director dealings. The document is not an annual or quarterly report, earnings release, or any other financial report. It specifically reports personal share transactions by company directors and executives, which matches the definition of Director's Dealing (DIRS). The document length is about 9805 characters, which is sufficient to contain detailed transaction information, not just an announcement or certification. Therefore, the correct classification is DIRS with high confidence.
2021-03-25 English
AZD1222 US PH3 PRIMARY ANALYSIS CONFIRMS EFFICACY
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It provides detailed information about the primary analysis results of the Phase III trial of the AZD1222 COVID-19 vaccine, including efficacy and safety data. The document is not an annual or quarterly report but a regulatory filing to inform the SEC and investors about significant clinical trial results. It does not contain comprehensive financial statements or management discussion typical of annual or interim reports. It is also not an earnings release, proxy statement, or other specific category. Given the nature of Form 6-K filings, which are used for current reports by foreign private issuers, and the detailed clinical trial results presented, this document fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2021-03-25 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.